Document Type : Original Article

Authors

1 Assistant Professor, Department of Biology Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.

2 Professor, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.

3 M.Sc. Student of Cellular and Developmental Biology, Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran

Abstract

Background and purpose: granulocyte colony-stimulating factor (G-CSF) has a major role in blood cells differentiation especially in neutrophils, therefore G-CSF widely has been used in treatment of chemotherapy-induced neutropenia. Different lines of evidence indicated that G-CSF is increased in inflammatory situation and has inflammatory characteristics. Unlike G-CSF, type I interferones (IFNs) have been shown to have anti-inflammatory effects. The aim of this study was to investigate whether type I IFNs can normalize the effects of G-CSF on blood factors.
Materials and methods: forty-two mice (male, eight weeks) were divided into six groups of seven, which includes Group 1 (control) injection of distilled water, Group 2 injection 200 µg/kg b.w. G-CSF, Group 3 injection 200 µg/kg b.w. Alfa interferon (IFN-α), Group 4 injection 200 µg/kg b.w. interferon beta (IFN-β), Group 5 injection 200 µg/kg b.w. G-CSF+200 µg/kg b.w. IFN-α, Group 6 injection 200 µg/kg b.w. G-CSF+200 µg/kg b.w. IFN-β. After 28 days, blood was taken from each mouse heart and blood biochemical parameters (Glucose, Triglyceride, Cholestrol) was investigated.
Results: surprisingly, in most cases, the G-CSF and type one IFNs alone or simultaneously reduced the levels of Glucose, triglycerides and cholesterol. Also the reduction of glucose, triglycerides and cholesterol were higher in G-CSF and INFs in compare with G-CSF alone. Our data raise the possibility that, G-CSF and INF-α/β have some similarity in signaling pathway which has to be investigated.

Keywords

Main Subjects

Saidi Nia A, Sadeghi Zade M, Maghsoodi N, Akbari B, Fallah J, Karimi M. CDNA cloning of human granulocyte colony stimulating factor (hG-CSF). Modares Journal of Med Sci. 2002; 5(1): 55-64. [in Persian]
[2] Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay AJ, et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol. 2003; 170(9): 4432-6.
[3] Eyles JL, Hickey MJ, Norman MU, Croker BA, Roberts AW, Drake SF, et al. A key role for G-CSF-induced neutrophil production and trafficking during IFNlammatory arthritis. Blood. 2008; 112(13): 5193-5201.
 
[4] Marshall JC. The effects of granulocyte colony-stimulating factor in preclinical models of infection and acute inflammation. Shock. 2005; 24: 120-9.
[5] Inderbitzin D, Beldi G, Sidler D, Studer P, Keogh A, Bisch-Knaden S, et al. Granulocyte colony-stimulating factor supports liver regeneration in a small-for-size liver remnant mouse model. J Gastrointest Surg. 2007; 11(3): 280-285.
[6] Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009; 5(10): 554-559.
[7] Clark R, Cubeddu MA, Luigi X. Lippincott's illustrated reviews. Pharmacology. 2009.
[8] Clark R, Cubeddu MA, Luigi X. Lippincott's illustrated reviews. Pharmacology. 4th Edition. 2009.
[9] Billiau A. Anti-inflammatory properties of Type I interferons. Antiviral Res. 2006; 71(2-3): 108-16.
[10] Benveniste EN, Qin H. Type I interferons as anti-IFNlammatory mediators. Sci STKE. 2007; 416: 70.
[11] Kenneth EB, Suzanne ML. Principles of clinical chemistry. Zahedan. 1993. [in Persian]
[12] Cho H, Kelsall BL. The role of type I interferons in intestinal IFNection, homeostasis, and IFNlammation. Immunological Reviews. 2014; 260(1): 145-67.
[13] Atsumi T, Cho YR, Leng L, McDonald C, Yu T, Danton C, et al. The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol. 2007; 179(8): 5399-406.
[14] Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012; 15(5): 635-45.
[15] Stapleton PA, Goodwill AG, James ME, Brock RW, Frisbee JC. Hypercholesterolemia and microvascular dysfunction: interventional strategies. J Inflamm (Lond). 2018; 7: 54.
[16] Glaspy JA, Souza L, Scates S, Narachi M, Blatt L, Ambersley J, et al. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b. J Immunother. 1992; 11(3): 198-208.
[17] Shoelson SE, Lee J, Goldfine AB. IFNlammation and insulin resistance. J Clin Invest. 2006; 116(7): 1793-1801.
[18] Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004; 45(7): 1169-96.
[19] Ning Y, Bai Q, Lu H, Li X, Pandak WM, Zhao F, et al. Overexpression of mitochondrial cholesterol delivery protein, StAR, decreases intracellular lipids and IFNlammatory factors secretion in macrophages. Atherosclerosis. 2009; 204(1): 114-120.
[20] Feingold KR, Hardardóttir I, Grunfeld C. Beneficial effects of cytokine induced hyperlipidemia. Z Ernahrungswiss. 1998; 37: 66-74.
[21] Ferroni P, Basili S, Davi G. Platelet activation, IFNlammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol. 2003; 1(2): 157-169.
[22] Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, et al. Atherosclerosis and liver IFNlammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 2007; 8(9): 200.
[23] Han Y, Yan L, Han G, Zhou X, Hong L, Yin Z, et al. Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy. Cytotherapy. 2008; 10(4): 390-396.
[24] Abbas Abol K, Lichman Andro H, Poober Jordan S. Cellular and Molecular Immunology. Mashhad: SID Mashhad. 2001.
[25] Lutz PG, Moog-Lutz C, Cayre YE. Signaling revisited in acute promyelocyti leukemia. Leukemia. 2002; 16(10): 1933-1939.
[26] Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke. 2003; 34(3): 745-751.
[27] Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004; 5(12): 253.
[28] Crow MK. Type I interferon in organ-targeted autoimmune and IFNlammatory diseases. Arthritis Res Ther. 2010; 12 Suppl 1: S5.
[29] Shen H, Zhang M, Minuk GY, Gong Y. Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. BMC Cell Biol. 2002;